Cardiff Oncology, Inc. Announces Conference Call to Discuss Financial Results and Clinical Programs
On Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT in San Diego, Cardiff Oncology, Inc., a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, will be holding a conference call to discuss their financial results for the first quarter ended March 31, 2024 and provide updates on their clinical programs targeting various indications such as colorectal cancer, pancreatic cancer, small cell lung cancer, and triple negative breast cancer.
During the conference call, Cardiff Oncology will discuss their financial results and provide updates on their clinical programs. The company’s lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care therapeutics to target tumor vulnerabilities and deliver superior clinical benefit.
Individuals interested in listening to the live conference call can do so by using the webcast link in the “Investors” section of the company’s website. A replay of the call will be available in the investor relations section on the website following its completion. For more information about Cardiff Oncology and their clinical programs, visit their website at https://www.cardiffoncology.com.
For any inquiries regarding this announcement or for media inquiries please contact Grace Spencer from Taft Communications at 609-583-1151 or email grace@taftcommunications.com